PolyNovo Keeps Bull Despite Sales Slowdown -- Market Talk
Dow Jones2026/07/30 05:010501 GMT - PolyNovo keeps its bulls at Morgans despite the medical-device maker's 2H revenue slowdown. Maintaining a buy rating on the stock, the Australian broker's analysts tell clients in a note that, while sales disappointed, cash generation is strong. They think this indicates the wound-treatment specialist is in a good position to deliver material Ebitda growth in each of its next two fiscal years. Morgans analysts say they remain confident that revenue growth can return above-20% levels in fiscal 2027, pointing out that 15.5% U.S. sales growth in fiscal 2026 was said by management to reflect some seasonality and shifts in insurance reimbursements. Morgans cuts its target price by 5.1% to 1.48 Australian dollars. Shares are down 3.4% at A$0.85. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
July 30, 2026 01:01 ET (05:01 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic IPO frenzy! Subscription demand several times oversubscribed, targeting a valuation of 1.4 trillions USD
Anthropic's upcoming IPO has sparked strong market enthusiasm, with subscription demand reaching several times the offering. The company plans to raise up to 90.4 billions USD through the IPO and private placement, potentially setting a new record for the largest listing in history. Although its valuation target of 1.4 trillions USD is slightly lower than previously expected, the market response remains extremely enthusiastic, fueled by robust institutional anchor demand.
BUZZ-Satellogic shares surge on strong third-quarter results
Crypto prices
More
